GlobeNewswire Inc.··NaKeros Therapeutics' Rinvatercept Shows Promise in Neuromuscular Disease Trial
Keros Therapeutics presented Phase 1 data for rinvatercept showing good tolerability and increased muscle mass, planning Phase 2 trials in DMD and ALS.
KROSPhase 1 clinical trialPhase 2 trials